Anaplastic Thyroid Cancer Clinical Trial
Official title:
A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT]
The purpose of the study is to determine the safety and efficacy of combretastatin combined with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).
Anaplastic thyroid carcinoma (ATC) is a high-grade neoplasm, characterized by an aggressive clinical course with brief survival, and refractoriness to currently available local and systemic modalities of treatment. There is no standard therapy for ATC, and no randomized comparative trials have been known to be conducted in this disease. One potential strategy is to combine the anti-tumor activity of the vascular disrupting agent combretastatin with conventional cytotoxic agents. This study will compare the overall survival of ATC patients treated with the triplet combination of combretastatin, paclitaxel, and carboplatin compared with the doublet treatment of paclitaxel and carboplatin. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04420754 -
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
|
Phase 1 | |
| Completed |
NCT02152137 -
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04552769 -
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04400474 -
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
|
Phase 2 | |
| Completed |
NCT02688608 -
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
|
Phase 2 | |
| Terminated |
NCT00095693 -
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01240590 -
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05819593 -
Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
|
||
| Active, not recruiting |
NCT04579757 -
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06362694 -
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
|
Phase 2 | |
| Recruiting |
NCT06374602 -
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
|
Phase 2 | |
| Withdrawn |
NCT01701349 -
Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03085056 -
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
|
Early Phase 1 | |
| Recruiting |
NCT01774279 -
interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
|
||
| Terminated |
NCT00126568 -
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
|
Phase 2 | |
| Completed |
NCT02244463 -
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05696548 -
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
|
Phase 2 | |
| Terminated |
NCT00603941 -
A Phase 1/2 Study of CS7017, an Oral PPARĪ³ Agonist, in Combination With Paclitaxel
|
Phase 1/Phase 2 | |
| Completed |
NCT00280852 -
Review of Multimodality Management of Anaplastic Thyroid Cancer
|
N/A | |
| Recruiting |
NCT04238624 -
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
|
Phase 2 |